RNI NO. MAHENG/2007/23118

Mar 1 - 15, 2025 [Bi-M

All Your Ingredients In One Magazine

Ingredients SOUTH ASIA

A Saffron Media Publication
Vol. 18, Issue 15, Pages 24

Cos outsourcing API development to CDMOs

DR SANJAY AGRAWAL

The pharmaceutical industry in North America is undergoing a transformative evolution, with the Active Pharmaceutical Ingredient (API) market at its very core. APIs are the biologically active components of drugs, and their demand is directly linked to the growing need for innovative, effective, and accessible healthcare. In recent years, the API sector has become a strategic focal point - not just in terms of healthcare delivery, but also as a cornerstone of supply chain resilience, regulatory compliance, and economic opportunity.

In this article, we explore the dynamics propelling the growth of the North American API market, key trends, regulatory impacts, domestic manufacturing resurgence, and what the future holds.

1. Understanding the API Landscape in North America

Active Pharmaceutical Ingredients are the chemical compounds that bring medicinal products to life. They are the muscle behind the medicine - whether it's the paracetamol in your painkiller or the insulin in your diabetes treatment.

North America, particularly the US, has long been a hub for pharmaceutical innovation. However, until recently, API production had been outsourced primarily to countries like China and India due to lower production costs. Now, several catalysts - geopolitical tensions, pandemic-induced supply chain disruptions, and a call for pharmaceutical sovereignty - are triggering a recalibration.

According to recent industry reports, the North American API market was valued at US$ 50+ billion in 2023, and is expected to grow at a CAGR of over 6% through 2030.

2. What's Fueling the Growth of APIs in North America?

Several key factors are supercharging API demand and production across the continent:

a. Surge in Chronic Diseases

North America faces a high burden of chronic diseases like cancer, diabetes, and cardiovascular ailments. The aging population and sedentary lifestyles have only added fuel to this fire. As a result, there's a consistent and rising need for high-quality APIs that form the base of life-saving medications.

b. Push for Domestic Manufacturing

The pandemic was a wake-up call. With disrupted supply chains and over-reliance on imports, the US and Canada began to reevaluate their pharmaceutical independence. Government incentives and policies are now supporting domestic API production, giving a massive push to homegrown manufacturers.

> The FDA and Health Canada are improving their frameworks for quicker API approvals, especially for generics and biosimilars

c. Biologics and Specialty Drugs

Biotech innovations are reshaping the pharmaceutical sector. Biologic APIs, which require advanced capabilities and infrastructure, are gaining ground. North American firms are leading in the development of monoclonal antibodies, gene therapies, and mRNA-based drugs - each of which relies on complex API formulations.

d. Regulatory Streamlining

The FDA and Health Canada are improving their frameworks for quicker API approvals, especially for generics and biosimilars. This regulatory clarity makes North America more attractive for investment and manufacturing.

3. Key Trends Shaping the API Market

The API market is no longer just about volume- it's about value, versatility, and velocity. Here are the top trends:

i. Shift Toward High-Potency APIs (HPAPIs)

From oncology to hormone therapies, high-potency APIs are gaining importance. These APIs require specialised facilities and safety protocols, and North American manufacturers are investing heavily in this niche.

ii. Growth of CDMOs (Contract Development and Manufacturing Organisations)

Pharma companies are outsourcing API development to CDMOs to streamline operations. North America is seeing a rise in such partnerships, especially in the small molecule and biotech segments.

iii. Sustainability in API Production

Green chemistry and environmentally responsible manufacturing are becoming the new normal. Companies are exploring solvent recovery systems, energy-efficient reactors, and waste minimisation processes to align with ESG goals.

iv. Integration of AI and IoT in API Manufacturing

Smart manufacturing is revolutionising the API production floor. Real-time monitoring, predictive maintenance, and digital twins are being used to enhance quality control, reduce downtime, and maintain compliance.

4. Regulatory Landscape: The Tightrope Walk

The regulatory climate in North America is stringent, but for good reason. Ensuring patient safety and drug efficacy means APIs must meet high standards for purity, potency, and stability.

- ***FDA's Role:*** The US FDA's Drug Master File (DMF) system for APIs ensures that detailed, confidential information about facilities, processes, and materials is maintained. The FDA also performs regular inspections and enforces strict cGMP (current Good Manufacturing Practices).
- ***Health Canada's Vigilance:*** Canada operates under a similar structure, requiring establishments to be licensed and follow GMP for APIs. Their ongoing collaboration with US regulators helps create a more integrated North American API ecosystem.

CONTINUED ON p25▶

Major overhauls in legacy mfg units

CONTINUED FROM p24

While these regulations raise the bar, they also increase manufacturing complexity and compliance costs. However, companies that successfully meet these standards build reputations of reliability and quality, factors that are invaluable in the global pharma market.

5. Strategic Players and Investments

Several major companies are investing aggressively in API infrastructure in North America. Notable examples include:

- ***Pfizer:*** Building state-of-the-art API facilities in the US to support biologics and Covid-related drug production.
- ***Thermo Fisher Scientific:*** Expanding its API manufacturing capacity through acquisitions and internal projects.
- ***Eli Lilly and Co.:*** Investing billions into new US-based API and injectable manufacturing plants.
- ***Ampac Fine Chemicals:*** Strengthening its capabilities in high-containment APIs.

Additionally, private equity is increasingly eyeing API manufacturers, signaling confidence in the sector's profitability and long-term relevance.

6. Challenges on the Horizon

Despite the upbeat momentum, the API market is not without hurdles:

Cost-Competitiveness

Manufacturing in North America is more expensive than in Asia due to labour, energy, and regulatory compliance. Bridging this gap requires tech innovation, automation, and government subsidies.

Talent Shortage

There's a growing need for skilled chemists, engineers, and regulatory professionals. Workforce development and STEM education must keep pace with industry needs.

Environmental Compliance

As ESG becomes a boardroom priority, meeting environmental standards for waste management and emissions will require major overhauls in legacy manufacturing units.

7. Future Outlook: Reshaping the Global API Map

The API market in North America is on a bullish trajectory. Here's what we can expect in the next five years:

- API nationalism will increase, with governments favouring local production and supply chain sovereignty.
- Advanced therapies, especially gene and cell therapies, will drive demand for complex APIs.
- Cross-border partnerships within North America (US-Canada-Mexico) may form a regional API powerhouse.
- Smart factories will become the norm- integrating automation, AI, and IoT to meet the twin demands of scalability and compliance.

In a world that's increasingly uncertain, API resilience is becoming the new health security. North America is well-positioned to not only meet its domestic needs but also emerge as a trusted global supplier.

Conclusion: The API Awakening

The API market in North America is no longer playing catch-up - it's setting the pace. Driven by innovation, necessity, and a renewed sense of strategic importance, the continent is writing a bold new chapter in pharmaceutical manufacturing. For stakeholders - from policy makers to pharma giants, investors to technologists - this is a market to watch, shape, and lead.

As we move into a post-pandemic world, the question is no longer "Will North America lead in APIs?" It's "How fast will the rest catch up?"

(The author is scientific advisor of Alkomex GBN Pharma Group USA)